stutes
03 Oct 2019
Need new CEO Share price drop should, in my opinion, give the board the reason for new CEO. How many times do we see the CFO giving presentations rather than CEO?
stutes
03 Oct 2019
Need new CEO Weve seen trial delays on Pisces, mixed hrp data, ramp up of overheads, - time for a new CEO who will deliver on Pisces and creates value rather than losses, rtc.
stutes
02 Oct 2019
Latest results of eye trial ReNeuron reports mixed results from blindness disease treatment trial 2 October 2019 | 09:28am StockMarketWire.com - Cell-based therapeutics developer ReNeuron said it had gleaned positive data from a trial of a treatment for blindness-causing disease retinitis pigmentosa, though efficacy results were mixed. The Phase 1/2a clinical trial involved the company’s human retinal progenitor cell therapy candidate. The observed efficacy was rapid and profound in the first three patients in the Phase 2a segment of the study, ReNeuron said. However, it added that while efficacy in subsequent patients had also been seen, it was at a lower rate and magnitude, with the ultimate extent of improvement not yet known as the study was ongoing. ‘Overall, the improvements to date represent a clear signal of efficacy in a patient population where inexorable disease progression is the norm,’ ReNeuron said. At 9:28am: [LON:RENE] ReNeuron Group PLC share price was -30p at 240p
stutes
02 Oct 2019
Latest results of eye trial The study at 9 months appears to show the number of words is fewer than st 6 months. I wondered why Rene announced the results ahead of the medical conference. Overall I think the CEO should follow the example of Tesco’s CEO re time and go.
stutes
02 Oct 2019
Latest results of eye trial Think City fearful of Woodford selling?
loper
02 Oct 2019
Latest results of eye trial The results announced today re the phase 1/2a trial in retinitis pigmentosa are pretty good - quite sensational actually. So far as I know there are no other trials anything like as good as this. Additionally, the cells used are allogeneic and appear to be non allergenic. RP is quite a small group of patients who will be greatly benefited by the therapy. The prevalence in the US is The prevalence in the US and Europe is approximately 1:3,500 to 1:4,000. Haim 2002. It should be noted that the treatment for RP should be able to be used also for the much larger group of people who suffer from AMD - age related macular degeneation, ie fading eyesight of old age. The prevalence in the UK is 2.4% at age 50 and 12.2% at age 80. Approximately 11 million individuals are affected with AMD in the United States alone, with a global prevalence of 170 million. AMD is thereby the leading cause of visual disability in the industrialized world and the third leading cause globally . Aging is the greatest risk factor. The prevalence of AMD in the U.S. is anticipated to increase to 22 million by the year 2050, while the global prevalence is expected to increase to 288 million by the year 2040. In the U.S., the prevalence of AMD is similar to that of all invasive cancers combined and more than double the prevalence of Alzheimer’s Disease. The share price started off the day at 300p and has since been bashed down by the usual gang of day/swing trader drongos to 210p or so. A buying oppotunity ?
stutes
10 Sep 2019
Stroke data delay How many delays will it take before Reneuron changes CEO? Consider how Tapestry Inc fired its CEO for slow integration of business units. Time for a closer.
stutes
10 Sep 2019
Stroke data delay Rene had over 12 months planning the stroke trial and yet suffers one delay after another . Why didn’t they split 104 patients instead of only patients from USA say from Russia , Australia Canada, UK ? In my opinion the CEO should be held culpable for the delays. Time for a new CEO.
loper
19 Jul 2019
Woodford funds Company news says that the next reporting on the progress of retinal stem cells in October 2019. Likely to be good.
Ripley94
19 Jul 2019
Woodford funds Hope you closed that short last call … 230p when you posted on 7th , 192p by 27th June , back up to 240p now .
Ripley94
19 Jul 2019
Woodford funds RENE. XXXX Interesting table in news here 11th jury 2019 … 19 AIM Shares that have doubled in HI . This number 3 . Only have one QFI … but that has come of big fall just rebounding !!
stutes
15 Jul 2019
CEO has he delivered? Rene needs better management of its trials- weve seen too many delays, limited success in R&D developing pipeline. A new CEO could help to change things for the better.
stutes
12 Jul 2019
CEO has he delivered? In my opinion today’s appointment announcement of new business development post makes the case for a new CEO stronger . The key for me, has CEO delivered?
stutes
11 Jul 2019
CEO has he delivered? When CEO was appointed it was reported he had expertise in jvs and Rene would be able to gain from this expertise. Almost 5yrs to the day , the CEO has only one jv under his belt, excluding Fosun deal, and that is a deal with a US pharma. Overall 5yrs and only 2 deals and two trials stopped , I suggest the CEO needs to be changed for one who will deliver CTX and hrpc trials on time. In my opinion its time for Rene to come out of the sidelines and become the next UK Shire which means value adding m&a deals and faster trial success.
stutes
11 Jul 2019
Share price How can any quoted business lose 12% of its value on a volume of 228.6k and number of shares 31804617. In other words 1.05% of the shares created a 12% swing. Looks to me the market wants to conserve their cash or buy shares heavily discounted?
